

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 December 1999 (23.12.1999)

PCT

(10) International Publication Number
WO 99/65870 A3

(51) International Patent Classification⁶: **C07C 311/48**,
C07D 235/30, 309/12, 309/06, 307/20, 493/04, 215/48,
405/12, A61K 31/27, 31/34, 31/395

P.O. Box 13398, Research Triangle Park, NC 27709 (US).
LOWEN, Gregory, Thomas [US/US]; P.O. Box 315,
Williamsburg, VA 23187 (US).

(21) International Application Number: PCT/US99/13744

(74) Agents: **HALEY, James, F., Jr.**; Fish & Neave, 1251 Av-
enue of the Americas, New York, NY 10020 et al. (US).

(22) International Filing Date: 17 June 1999 (17.06.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/090,094 19 June 1998 (19.06.1998) US

(71) Applicant (for all designated States except US): **VERTEX
PHARMACEUTICALS INCORPORATED** [US/US];
130 Waverly Street, Cambridge, MA 02139-4242 (US).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,
BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHERRILL,
Ronald, George** [US/US]; Glaxo Wellcome Inc., Five
Moore Drive, P.O. Box 13398, Research Triangle Park,
NC 27709 (US). **HALE, Michael, R.** [US/US]; 42 Sunset
Road, Bedford, MA 01730 (US). **SPALTENSTEIN, An-
drew** [US/US]; Glaxo Wellcome Inc., Five Moore Drive,
P.O. Box 13398, Research Triangle Park, NC 27709 (US).
FURFINE, Eric, Steven [US/US]; Glaxo Wellcome Inc.,
Five Moore Drive, P.O. Box 13398, Research Triangle
Park, NC 27709 (US). **ANDREWS, Clarence, Webster,
III** [US/US]; Glaxo Wellcome Inc., Five Moore Drive,

Published:

— With international search report.

(88) Date of publication of the international search report:
15 March 2001

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE

(57) Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.